Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease, with a primary focus on pulmonary arterial hypertension (PAH). The IKT news feed highlights the company’s progress as it advances its lead investigational therapy, IKT-001, a prodrug of imatinib mesylate, through late-stage clinical development in PAH.
Visitors to this page can review company-issued press releases and related disclosures that describe Inhibikase’s clinical plans, regulatory interactions, and corporate developments. Recent news has covered the evolution of the IMPROVE-PAH clinical program for IKT-001, including the transition from a planned Phase 2b trial to a global pivotal Phase 3 study design following a Type C interaction with the U.S. Food & Drug Administration. The company also reports on its financial results, capital raises through private placements and underwritten public offerings, and changes in senior leadership and board composition.
Because Inhibikase is a clinical-stage company with no marketed products, its news flow is closely tied to research and development milestones, such as study protocol finalization, anticipated trial initiation timelines, and updates on the design of adaptive clinical studies in PAH. Corporate updates, including executive appointments and governance matters, are also reflected in its announcements. Investors and observers can use this news page to follow how Inhibikase describes the advancement of IKT-001 in pulmonary arterial hypertension and how the company positions itself within the cardiopulmonary disease space.
Inhibikase Therapeutics (Nasdaq: IKT) announced the first patient enrollment in IMPROVE-PAH, a global adaptive Phase 3 study of IKT-001 for pulmonary arterial hypertension dated April 7, 2026. The two-part trial includes Part A (~140 patients) with a 24-week PVR endpoint and Part B (~346 patients) with a 24-week 6MWD endpoint.
The protocol permits a 12-week dose-titration, sample-size re-estimation for Part B, up to ~180 global sites, and follows written responses received from the FDA supporting the revised pivotal design.
Inhibikase Therapeutics (Nasdaq: IKT) granted non-qualified stock options for an aggregate of 685,718 shares to five newly hired non-executive employees under its 2026 Inducement Equity Plan, effective March 31, 2026. The options carry a $1.68 exercise price, equal to the closing price on the effective date.
The awards have a 10-year term, with 25% vesting on the first anniversary and the remaining 75% vesting in 36 equal monthly installments. Grants were approved as inducements under Nasdaq Listing Rule 5635(c)(4).
Inhibikase Therapeutics (Nasdaq: IKT) reported full-year 2025 results and operational milestones on March 26, 2026. Key items: initiation of the global pivotal Phase 3 adaptive study IMPROVE-PAH for IKT-001, regulatory submissions in 20+ countries, FAST-EU acceptance, a $115 million public offering, and $178.8M cash at year-end.
2025 net loss was $48.3M versus $27.5M in 2024; R&D rose to $29.8M, including a $7.4M IPR&D write-off tied to the CorHepta acquisition.
Inhibikase Therapeutics (NASDAQ: IKT) priced an underwritten public offering to raise approximately $100.0 million in gross proceeds. The company is offering 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares. Common shares are priced at $1.45 each; pre-funded warrants at $1.449 each (reflecting a $0.001 exercise price). Underwriters have a 30-day option to buy up to 10,344,827 additional shares. The offering is expected to close on November 24, 2025, subject to customary closing conditions.
Jefferies, BofA Securities and Cantor are joint book-running managers; other managers include LifeSci Capital, Oppenheimer, H.C. Wainwright and Ladenburg Thalmann.
Inhibikase Therapeutics (NASDAQ: IKT) on Nov 20, 2025 announced a proposed underwritten public offering of common stock and, for some investors, pre-funded warrants exercisable for common stock. The company also intends to grant underwriters a 30‑day option to purchase up to an additional 15% of the shares at the public offering price, less underwriting discounts and commissions.
The offering is being made from a shelf registration on Form S-3 (No. 333-288213) declared effective June 27, 2025, is subject to market and other conditions, and may not be completed. Jefferies, BofA Securities and Cantor are joint book‑running managers; LifeSci Capital and Oppenheimer are co‑lead managers; H.C. Wainwright and Ladenburg Thalmann are co‑managers. A preliminary prospectus supplement will be filed with the SEC.
Inhibikase Therapeutics (Nasdaq: IKT) plans to initiate a global pivotal Phase 3 study of IKT-001 in pulmonary arterial hypertension in Q1 2026. The adaptive two-part IMPROVE-PAH trial expects Part A as a double-blind, placebo-controlled study in 140 patients with primary endpoint PVR at Week 24, and Part B in 346 patients with primary endpoint 6MWD at Week 24. The design includes a 12-week dose-titration, uninterrupted enrollment between parts, and potential sample-size re-estimation; the study may run in about 180 global sites. IKT-001 is described as a prodrug of imatinib with expected improved gastrointestinal tolerability and a stated potential to accelerate an NDA timeline by ~3 years.
Inhibikase Therapeutics (Nasdaq: IKT) reported third quarter 2025 results and clinical progress on Nov 14, 2025. The company said it expects to initiate the Phase 2b IMPROVE-PAH trial of IKT-001 in Q4 2025, a randomized, double-blind, placebo-controlled study of ~150 PAH participants randomized 1:1:1 to 300 mg, 500 mg or placebo once daily for 26 weeks; primary endpoint is change in pulmonary vascular resistance at Week 26 and an interim safety review is planned at 12 weeks for ≥50 patients. Bioequivalence testing showed 500 mg IKT-001 has comparable exposure to 383 mg imatinib. Financials: cash and marketable securities were $77.3M as of Sept 30, 2025; Q3 net loss was $11.9M ($0.13/share). The company completed the CorHepta acquisition in Feb 2025 and named Timothy Pigot Chief Commercial and Strategy Officer.
Inhibikase Therapeutics (Nasdaq: IKT) has appointed Timothy Pigot as Chief Commercial and Strategy Officer to strengthen its leadership team. Pigot brings over 30 years of pharmaceutical industry experience, most recently serving as Chief Commercial Officer at Aerovate Therapeutics.
The appointment comes as Inhibikase advances IKT-001 toward late-stage clinical trials in pulmonary arterial hypertension (PAH). Pigot's extensive background includes leadership roles at MyoKardia, Gilead Sciences, and Pfizer, where he led commercial strategies for various therapeutic areas including PAH, cardiopulmonary, CNS, and oncology.
Inhibikase Therapeutics (Nasdaq: IKT) reported Q2 2025 financial results and provided updates on its PAH drug development program. The company is preparing to launch IMPROVE-PAH, a Phase 2b clinical study for IKT-001, their re-engineered prodrug of imatinib mesylate, in the second half of 2025.
The study will involve 150 PAH participants randomized to receive either 300mg IKT-001, 500mg IKT-001, or placebo. Previous studies showed imatinib's efficacy in PAH, with patients on 400mg achieving a 45-meter improvement in 6-minute walk distance. The company ended Q2 2025 with $87.7 million in cash and reported a net loss of $9.9 million ($0.11 per share).
Inhibikase Therapeutics (NASDAQ: IKT) reported its Q1 2025 financial results and recent developments. The company reported a net loss of $13.7 million ($0.15 per share) compared to $4.6 million in Q1 2024. R&D expenses increased to $10.5 million, including a $7.4 million non-cash charge for the CorHepta acquisition. SG&A expenses rose to $5.2 million from $2.0 million year-over-year.
The company strengthened its leadership team with key appointments, including Mark Iwicki as CEO. IKT is advancing IKT-001 toward a Phase 2b clinical trial in Pulmonary Arterial Hypertension (PAH) expected to begin in H2 2025. The company maintains a strong cash position of $93.2 million as of March 31, 2025.